Skip to main content
Equibles
RGEN logo

RGEN · Repligen Corp

Track RGEN — free

Use RGEN with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about RGEN

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$176.36 +10.21 (+6.15%) At close · Aug 19
Market Cap
$9.36B
Shares
56.44M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$176.36 Open$172.74 Day$170.00–179.87 52W close$102.87–176.36 Avg vol 30d1.2M Short int6.1M · 10.9% float · 3.9d Short vol40% Last earningsJul 22, 2026 DataJan 2020–Aug 2026 Filing10-Q · Jul 29

Up next

Next earnings call
Oct 15, 2026 Est · unconfirmed · in 8 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Jul 29, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
      Market backdrop VIX 14.9 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +26%
      above
      Price vs 50-day avg +22%
      above
      RSI (14) 74
      overbought
      MACD trend Positive
      52-week position 100%
      near high
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +26%
      trailing
      6-month return +32%
      trailing
      YTD return +8%
      this year
      Relative strength +20%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $145 › 200d $140 — 50d above 200d
      Institutional flow Accumulating
      +8% holders QoQ · +99 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      10.87% of float · ▲ +5.5% MoM · 3.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      481 holders — near 3-yr high, broad support
      Squeeze score 77
      high risk · 0–100
      Fundamentals
      Excellent
      Revenue growth +35%
      Y/Y
      EPS growth +287%
      Y/Y
      Free cash flow $93.9M
      Buyback $25.0M
      authorized
      Balance sheet $23.8M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 46%
      annualized · 1-yr
      Max drawdown −40%
      past year
      ATR 4.0%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 2 of last 3
      Latest guidance · from the 8-K filed Jul 28, 2026
      Total Reported Revenue · FY 2026 $813M – $835M
      Organic Growth · FY 2026 10.5% – 13.5%
      Gross Margin · FY 2026 Non-GAAP 53.7% – 54.2%
      Other Income (Expense) · FY 2026 Non-GAAP $19M
      Adjusted EBITDA Margin · FY 2026 Non-GAAP 20.6% – 21%
      Operating Margin · FY 2026 Non-GAAP 15.7% – 16%
      Income from Operations · FY 2026 Non-GAAP $128M – $134M
      Earnings Per Share - Diluted · FY 2026 Non-GAAP $2.03 – $2.09
      Net Income · FY 2026 Non-GAAP $115.5M – $118.5M
      Prior guidance period ended · from the 8-K filed Oct 28, 2025
      Total Reported Revenue · FY 2025 $729M – $737M
      Total Reported Revenue · FY 2025 $729M – $737M
      Organic Growth · FY 2025 12% – 13.5%
      Organic, Non-COVID Growth · FY 2025 14% – 15.5%
      Non-COVID Growth · FY 2025 17% – 18%
      Gross Margin · FY 2025 51.5% – 52.5%
      Income from Operations · FY 2025 $50M – $52M
      Gross Margin · FY 2025 52% – 53%
      Income from Operations · FY 2025 $98M – $100M
      Operating Margin · FY 2025 13.5%
      Operating Margin · FY 2025 7%
      Other Income (Expense) · FY 2025 $7.5M
      Other Income (Expense) · FY 2025 $21M
      Adjusted EBITDA Margin · FY 2025 19%
      Tax Rate on Pre-Tax Income · FY 2025 17% – 18%
      Net Income · FY 2025 $46.5M – $48M
      Tax Rate on Pre-Tax Income · FY 2025 21% – 22%
      Earnings Per Share - Diluted · FY 2025 $1.65 – $1.68
      Earnings Per Share - Diluted · FY 2025 $0.82 – $0.85
      Net Income · FY 2025 $93.5M – $95M
      Guided vs delivered · last 3 settled
      Total Reported Revenue FY 2025
      guided $729M – $737M
      $738.26M Beat +0.7%
      Earnings Per Share - Diluted FY 2025
      guided $0.82 – $0.85
      $0.86 Beat +3.0%
      Full year revenue full year 2023
      guided $635M – $645M
      $632.36M Miss −1.2%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 2 · 4
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +26% Bullish
      Price vs 50-day avg
      +22% Bullish
      RSI (14)
      74 Bearish
      MACD trend
      Positive Bullish
      52-week position
      100% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $145 › 200d $140 — 50d above 200d
      Institutional flow Accumulating
      +8% holders QoQ · +99 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      10.87% of float · ▲ +5.5% MoM · 3.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      481 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $103 Now $176 · 100% Range high $176
      vs 200-day avg +26% vs 50-day avg +22%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      ADJUSTED EBITDA (NON-GAAP) non-GAAP $83.78M Six Months Ended June 30, 2026 —
      ADJUSTED EBITDA MARGIN (NON-GAAP) non-GAAP 21% Six Months Ended June 30, 2026 —
      ADJUSTED EPS (NON-GAAP) - DILUTED non-GAAP $1.02 Six Months Ended June 30, 2026 —
      ADJUSTED INCOME FROM OPERATIONS (NON-GAAP) non-GAAP $63.91M Six Months Ended June 30, 2026 —
      ADJUSTED NET INCOME (NON-GAAP) non-GAAP $57.93M Six Months Ended June 30, 2026 —
      ADJUSTED NET INCOME MARGIN (NON-GAAP) non-GAAP 14.5% Six Months Ended June 30, 2026 —
      ADJUSTED OPERATING (EBIT) MARGIN (NON-GAAP) non-GAAP 16% Six Months Ended June 30, 2026 —
      EBITDA (NON-GAAP) non-GAAP $54.06M Six Months Ended June 30, 2026 —
      ORGANIC ADJUSTED OPERATING MARGIN (NON-GAAP) YEAR-OVER-YEAR CHANGE non-GAAP 3.3% Six Months Ended June 30, 2026 —
      ORGANIC REVENUE GROWTH (NON-GAAP) non-GAAP 12% Six Months Ended June 30, 2026 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Medical Instruments & Supplies — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      RGEN
      Repligen Corp
      this stock
      		$9.36B +7.6% +35.1% — 10.9%
      ISRG
      Intuitive Surgical Inc
      		 $137.90B -29.8% +20.5% 44.8 1.9%
      BDX
      Becton Dickinson & Co
      		 $49.24B — +8.2% — 3.7%
      MDLN
      Medline Inc.
      		 $45.86B -19.3% +11.5% — 2.6%
      ALC
      Alcon Inc
      		 $35.55B -5.8% +10.5% — 2.8%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      481
      % held
      118.2%
      Net QoQ
      +741.7K sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      578
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      6.1M
      Days to cover
      3.9d
      Change
      +320.8K sh
      View
      Short Volume
      Short vol %
      40%
      As of
      Aug 19, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      29
      Value
      $4.1K
      As of
      Jul 30, 2026
      View
      Off-Exchange
      Off-exchange %
      44.5%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Smart Money
      Congressional Trades Sell
      Member
      Lisa McClain
      Amount
      $1.0K–$15.0K
      Traded
      Oct 31, 2025
      View
      Financials
      Financials
      Revenue (FY)
      $141.2M
      Net income (FY)
      $48.9M
      EPS diluted
      $0.86
      View
      Buybacks
      Authorized
      $25.0M
      View
      Filings
      SEC Filings
      Latest
      10-Q
      Filed
      Jul 29, 2026
      This year
      12
      View
      Proposed Sales
      Value
      $79.5K
      Shares
      530
      Filed
      Jul 16, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jul 22, 2026
      View
      Investor Relations
      Latest news
      Repligen Reports Second Quarter 2…
      Published
      Jul 28, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      RGEN +6.4% +25.9% +32.0% +25.1% +7.6%
      SPY -0.4% +2.9% +11.6% +3.0% +12.8%
      vs SPY +6.9% +23.0% +20.4% +22.1% -5.2%

      Capital returns

      Buyback program · as of Dec 31, 2023
      Authorized
      $25.00M
      Spent (derived)
      —
      Remaining
      —

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 730272 CUSIP 759916109 13F (30d) 450 filings 424 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)